13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001643354
Total reported value
$20.9M
$20.9M
35 檔
26.6%
As reported in its official Q1 2026 Form 13F filing, Lion Point Capital, LP's tracked investment portfolio stood at $20.9M with 35 total positions.
In Q1 2026, Lion Point Capital, LP adopted a defensive or profit-taking posture, trimming 0 positions and completely liquidating 4 holdings to manage risk exposure.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | PRAX | Praxis Precision Medicines I | Stock-Other | 8.57% | -1.44% | — | |
| 2 | MLTX | Moonlake Immunotherapeutics | Stock-Other | 7.52% | -1.23% | — | |
| 3 | RPRX | Royalty Pharma plc | Stock-Healthcare | 6.14% | -0.40% | — | |
| 4 | MIST | Milestone Pharmaceuticals In | Stock-Other | 5.83% | -0.57% | +8.61% | |
| 5 | GERN | Geron CORP | Stock-Other | 5.15% | -1.61% | — | |
| 6 | SNDX | Syndax Pharmaceuticals Inc | Stock-Other | 5.03% | -1.27% | — | |
| 7 | ARDX | Ardelyx Inc | Stock-Other | 4.61% | -1.47% | — | |
| 8 | FENC | Fennec Pharmaceuticals Inc | Stock-Other | 4.13% | +1.65% | — | |
| 9 | BNTC | Benitec Biopharma Inc | Stock-Other | 3.95% | +0.02% | — | |
| 10 | SRPT | Sarepta Therapeutics Inc | Stock-Healthcare | 3.71% | -1.26% | — | |
| 11 | IRON | Disc Medicine Inc | Stock-Other | 3.10% | -0.27% | — | |
| 12 | CUE1EUR | Cue Biopharma Inc | Stock-Other | 3.03% | -3.03% | EXIT | |
| 13 | CMPS | Compass Pathways PLC | Stock-Other | 2.64% | +2.77% | +37.93% | |
| 14 | BHVN | Biohaven Ltd. | Stock-Other | 2.61% | +1.07% | — | |
| 15 | LNTH | Lantheus Holdings Inc | Stock-Healthcare | 2.49% | +0.43% | — | |
| 16 | JSPR | Jasper Therapeutics Inc | Stock-Other | 2.44% | -1.50% | — | |
| 17 | HUMA | Humacyte Inc | Stock-Other | 2.36% | +0.07% | +30.00% | |
| 18 | VTRS | Viatris Inc | Stock-Healthcare | 2.24% | -0.14% | — | |
| 19 | KURA | Kura Oncology Inc | Stock-Other | 2.24% | +0.17% | — | |
| 20 | BBIO | Bridgebio Pharma Inc | Stock-Healthcare | 2.22% | -0.44% | — | |
| 21 | DYN | Dyne Therapeutics Inc | Stock-Other | 1.95% | -0.04% | — | |
| 22 | RCKT | Rocket Pharmaceuticals Inc | Stock-Other | 1.84% | -0.43% | — | |
| 23 | PCRX | Pacira Biosciences Inc | Stock-Other | 1.82% | -0.18% | — | |
| 24 | EWTX | Edgewise Therapeutics Inc | Stock-Other | 1.71% | +0.06% | — | |
| 25 | MLYS | Mineralys Therapeutics Inc | Stock-Other | 1.70% | -0.34% | — | |
| 26 | MCRB | Seres Therapeutics Inc | Stock-Other | 1.67% | -0.48% | — | |
| 27 | JANX | Janux Therapeutics Inc | Stock-Other | 1.58% | -0.18% | — | |
| 28 | QURE | uniQure N.V. | Stock-Other | 1.44% | +1.80% | — | |
| 29 | RGNX | Regenxbio Inc | Stock-Other | 1.33% | +0.19% | — | |
| 30 | AZTA | Azenta Inc | Stock-Other | 1.22% | -0.05% | — | |
| 31 | INVA | Innoviva Inc | Stock-Other | 1.14% | -0.25% | — | |
| 32 | GHRS | GH Research PLC | Stock-Other | 0.86% | +0.45% | — | |
| 33 | ARQT | Arcutis Biotherapeutics Inc | Stock-Other | 0.74% | -0.08% | — | |
| 34 | IPHA | Innate Pharma Sa-spons Adr | Stock-Other | 0.62% | +0.09% | — | |
| 35 | SPRB | Spruce Biosciences Inc | Stock-Other | 0.39% | -0.13% | — |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | MLTX | Moonlake Immunotherapeutics | +2.9% | — | Unchanged |
| 2 | RPRX | Royalty Pharma plc | +1.9% | — | Unchanged |
| 3 | PRAX | Praxis Precision Medicines I | +1.8% | — | Unchanged |
| 4 | GERN | Geron CORP | +1.2% | — | Unchanged |
| 5 | SNDX | Syndax Pharmaceuticals Inc | +1.1% | — | Unchanged |
| 6 | ARDX | Ardelyx Inc | +0.7% | — | Unchanged |
| 7 | LNTH | Lantheus Holdings Inc | +0.6% | — | Unchanged |
| 8 | CMPS | Compass Pathways PLC | +0.6% | +37.93% | Add |
| 9 | EWTX | Edgewise Therapeutics Inc | +0.5% | — | Unchanged |
| 10 | SRPT | Sarepta Therapeutics Inc | +0.5% | — | Unchanged |
| 11 | VTRS | Viatris Inc | +0.5% | — | Unchanged |
| 12 | INVA | Innoviva Inc | +0.3% | — | Unchanged |
| 13 | RCKT | Rocket Pharmaceuticals Inc | +0.3% | — | Unchanged |
| 14 | BBIO | Bridgebio Pharma Inc | +0.2% | — | Unchanged |
| 15 | JANX | Janux Therapeutics Inc | +0.2% | — | Unchanged |
| 16 | GHRS | GH Research PLC | +0.2% | — | Unchanged |
| 17 | DYN | Dyne Therapeutics Inc | +0.1% | — | Unchanged |
| 18 | PCRX | Pacira Biosciences Inc | 0% | — | Unchanged |
| 19 | ARQT | Arcutis Biotherapeutics Inc | -0.1% | — | Unchanged |
| 20 | SPRB | Spruce Biosciences Inc | -0.1% | — | Unchanged |
| 21 | IPHA | Innate Pharma Sa-spons Adr | -0.1% | — | Unchanged |
| 22 | HUMA | Humacyte Inc | -0.1% | +30.00% | Add |
| 23 | IRON | Disc Medicine Inc | -0.2% | — | Unchanged |
| 24 | KURA | Kura Oncology Inc | -0.2% | — | Unchanged |
| 25 | MLYS | Mineralys Therapeutics Inc | -0.3% | — | Unchanged |
| 26 | FENC | Fennec Pharmaceuticals Inc | -0.4% | — | Unchanged |
| 27 | BNTC | Benitec Biopharma Inc | -0.4% | — | Unchanged |
| 28 | QURE | uniQure N.V. | -0.4% | — | Unchanged |
| 29 | BHVN | Biohaven Ltd. | -0.4% | — | Unchanged |
| 30 | AZTA | Azenta Inc | -0.4% | — | Unchanged |
| 31 | CUE1EUR | Cue Biopharma Inc | -0.5% | — | Unchanged |
| 32 | RGNX | Regenxbio Inc | -0.7% | — | Unchanged |
| 33 | MCRB | Seres Therapeutics Inc | -0.8% | — | Unchanged |
| 34 | JSPR | Jasper Therapeutics Inc | -2% | — | Unchanged |
| 35 | MIST | Milestone Pharmaceuticals In | -2.1% | +8.61% | Add |
| 36 | DAWNGBX | Day One Biopharmaceuticals I | — | EXIT | Sold out |
| 37 | VTYXUSD | Ventyx Biosciences Inc | — | EXIT | Sold out |
| 38 | NERV | Minerva Neurosciences Inc | — | EXIT | Sold out |
| 39 | MRSN | Mersana Therapeutics Inc | — | EXIT | Sold out |
According to official SEC Form 13F filings, Lion Point Capital, LP reported a total U.S. public equity portfolio value of $20.9M across 35 disclosed positions in Q1 2026.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including PRAX, MLTX, RPRX) accounted for 26.6% of total reported equity market value during Q1 2026.
Top Position Liquidated / Trimmed
DAWNGBX
前期市值: $391.4K
During Q1 2026, Lion Point Capital, LP's top holdings by market value included PRAX (8.6%)、MLTX (7.5%)、RPRX (6.1%). The largest single position, PRAX, represented 8.6% of total portfolio value.
In Q1 2026, Lion Point Capital, LP made 7 total portfolio adjustments, initiating 0 new buys, adding to 3 positions, trimming 0 holdings, and fully liquidating 4 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.